-transparent.png){kind=logo}
Noradrenergic mechanisms have been postulated to account for the anticonvulsant and psychotropic effects of carbamazepine. In order to assess this possibility in man, cerebrospinal fluid (CSF) was obtained from affectively ill patients before and during treatment with carbamazepine (average duration 29 days) at doses averaging 860 mg/day, achieving blood levels of 8.86 micrograms/ml. Neither plasma nor CSF norepinephrine (NE) nor CSF 3-methoxy-4-hydroxy-phenylglycol (MHPG) was significantly altered by carbamazepine. Baseline medication-free values in 21 depressed patients were not predictive of the degree of subsequent clinical antidepressant response. CSF NE decreased in four manic patients treated with carbamazepine. The many effects of carbamazepine on noradrenergic mechanisms in animals are discussed in relationship to these first studies of carbamazepine in man.
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
May 1986,
Psychological medicine,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
June 1986,
The Journal of clinical psychiatry,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
December 1984,
Archives of general psychiatry,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
August 1994,
Archives of general psychiatry,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
May 1986,
Acta psychiatrica Scandinavica,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
September 1997,
The Psychiatric clinics of North America,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
January 1982,
The American journal of psychiatry,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
October 1988,
Journal of psychosocial nursing and mental health services,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
April 1988,
Clinical neuropharmacology,
R M Post, and
D R Rubinow, and
T W Uhde, and
J C Ballenger, and
C R Lake, and
M Linnoila, and
D C Jimerson, and
V Reus
August 1979,
Biological psychiatry,
